



Autolus Announces Oral Presentations for Two Novel CAR-T Therapies at the 2016 American Society of Hematology Annual Meeting

November 28, 2016 at 8:00 AM EST

London, 28 November 2016 – Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, announces that data on two of its novel cell therapies will be presented at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego, CA, December 3-6, 2016.

Details of the oral presentations are as follows:

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Abstract: #379 <https://ash.confex.com/ash/2016/webprogram/Paper92...>

Presenter: Lydia Sarah Hui Lee, Cancer Institute, University College London, UK

Time: Sunday December 4th: 12:00PM PST

Location: Grand Hall B, Manchester Grand Hyatt Hotel, San Diego

Targeting T-Cell Receptor β -Constant Domains for Immunotherapy of T-Cell Malignancies

Abstract: #811 <https://ash.confex.com/ash/2016/webprogram/Paper90...>

Presenter: Paul Maciocia, Cancer Institute, University College London, UK

Time: Monday December 5th: 10:30AM PST

Location: Ballroom 20A, San Diego Convention Center

– Ends –

Further information:

JW Communications

Julia Wilson +44 (0)7818 430877

juliawilsonuk@gmail.com

Notes for Editors:

About Autolus

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus' shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Arix Bioscience plc. For further information please visit the Company's website at: www.autolus.com